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Abstract
Type 1A diabetes mellitus (T1ADM) is a progressive autoimmune disease mediated by T
lymphocytes with destruction of beta cells. Up to now, we do not have precise methods to assess
the beta cell mass, "in vivo" or "ex-vivo". The studies about its genetic susceptibility show strong
association with class II antigens of the HLA system (particularly DQ). Others genetics associations
are weaker and depend on the population studied. A combination of precipitating events may occur
at the beginning of the disease. There is a silent loss of immune-mediated beta cells mass which
velocity has an inverse relation with the age, but it is influenced by genetic and metabolic factors.
We can predict the development of the disease primarily through the determination of four
biochemically islet auto antibodies against antigens like insulin, GAD65, IA2 and Znt8. Beta cell
destruction is chronically progressive but at clinical diagnosis of the disease a reserve of these cells
still functioning. The goal of secondary disease prevention is halt the autoimmune attack on beta
cells by redirecting or dampening the immune system. It is remains one of the foremost therapeutic
goals in the T1ADM. Glycemic intensive control and immunotherapeutic agents may preserve beta-
cell function in newly diagnosed patients with T1ADM. It may be assessed through C-peptide
values, which are important for glycemic stability and for the prevention of chronic complications
of this disease. This article will summarize the etiopathogenesis mechanisms of this disease and the
factors can influence on residual C-peptide and the strategies to it preservation.
We are presently going through a revaluation of the
knowledge acquired in the last decades regarding the etio-
pathogenesis of type 1 diabetes mellitus (T1DM).
Type 1 diabetes classification
Nowadays, we may subdivide T1DM in three groups from
the etiological point of view: autoimmune, idiopathic and
double. The autoimmune group is represented by: type
1A, which is polygenic and it is the most frequent type of
this disease, corresponding to approximately 80-90% of
all T1DM cases [1]. The other subtype of this group is the
latent autoimmune diabetes in adults (LADA)[2], which
appears after the age of 35 and is frequently associated
with other autoimmune endocrine diseases. The third
subtype includes called "monogenic" T1DM. They corre-
spond to T1DM of the autoimmune polyglandular syn-
drome type 1A [3] and of IPEX syndrome (Immune
Dysfunction, Polyendocrinopathy, Enteropathy, X-
linked) [4].
Published: 4 December 2009
Diabetology & Metabolic Syndrome 2009, 1:25 doi:10.1186/1758-5996-1-25
Received: 10 July 2009
Accepted: 4 December 2009
This article is available from: http://www.dmsjournal.com/content/1/1/25
© 2009 Dib and Gomes; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Diabetology & Metabolic Syndrome 2009, 1:25 http://www.dmsjournal.com/content/1/1/25
Page 2 of 8
(page number not for citation purposes)
Type 1B, also called idiopathic, has all the clinical features
of type 1A, but the autoimmune component is not
detected [5]. Another 1B subtype is the fulminant diabetes
most described in Asian peoples, mainly Japan, China and
Korea, characterized by a short clinical history, before to
the first acute metabolic decompensation, presents the
impairment of beta and alpha cells of the pancreatic islet
and no autoimmune etiology [6].
Finally, the denomination of mixed, 1.5 or double (type 1
plus type 2) diabetes has been proposed when we have the
type 1A (autoimmunity) plus type 2 (obesity, insulin
resistance, dyslipidemia) diabetes characteristics in the
same individual [7].
In this review, we will cover only autoimmune type 1A
diabetes.
Type 1 A diabetes
Type 1 A diabetes is a chronic inflammatory disease which
leads to selective destruction of beta cells in pancreatic
islets [8]. Such cells are affected by a process involving
specific cellular and humoral autoimmunity mechanisms
against their antigens. A failure of regulatory T cells (T-
regs) on this process is involved [9]. However, even
though type 1 A diabetes is one of the most widely studied
autoimmune diseases over the last decades, its complete
natural history has not been fully clarified yet.
One of the subtypes of type 1A diabetes is the "mono-
genic" diabetes, associated with the Autoimmune Polyg-
landular Syndrome Type 1 [10]. Such syndrome, also as
APECED (Autoimmune Polyendocrinopathy- Candidia-
sis-Ectodermal Dystrophy) is more frequent in children
and pre-puberal individuals and is associated with the
mutation of the autoimmune regulatory gene (AIRE),
located in chromosome 21, that it is important to the reg-
ulation of autoimmune mechanisms [3]. A change in this
gen results in autoimmune reactions to different antigens
expressed in peripheral tissues due to a failure in regulat-
ing the presentation of such antigens in the thymus for its
recognition as "self-antigens". As it is already known, a
large part of autoimmune regulation occurs at the thymus
level, so that when peripheral lymphocytes go through the
thymus, they receive information about antigens to which
they must react or not. When the individual suffers change
in the AIRE gene, the selection criteria fail and these
patients start to react against antigens to which they
should not react. Type 1 diabetes is observed in 13-20% of
these patients. They are generally referred by other special-
ists, because the first clinical manifestation, most of the
times, is not hyperglycemia. The most frequent manifesta-
tions of this syndrome are mucocutaneous candidiasis,
Addison's Disease and hypoparathyroidism [3]. It is inter-
esting that in such patients, the glutamic acid decarboxy-
lase antibodies (GADA), that in classical type 1A diabetes
indicate pancreatic β cell lesion, are more related to the
presence of enteropathy [3].
The second "monogenic" subtype of type 1 A diabetes is a
rare type of diabetes which occurs in children and is asso-
ciated with changes in genes located in chromosome X
[11]. In this type of diabetes, children present mutation in
the gene which codifies the express of FOX-P3 in CD4+
and CD25+ cells. Such changes lead to a disability of gen-
erating regulatory T cells and the development of early
autoimmunity against several organs. Thus, it is character-
ized by the onset of a different type of diabetes, dependent
on exogenous insulin, enteropathy, growth deficiency and
early death in such children [4].
Nevertheless, the polygenic group type 1 A diabetes is the
most frequent form of T1DM and it is accountable for
approximately 90% of these cases.
Genetic Predisposition
Type 1 A diabetes is considered by some authors a poly-
genic and by others, an oligogenic, but heterogeneous dis-
ease. To date, several loci in different chromosomes are
related to the genetic susceptibility of this type of diabetes
[12]. Such locis are denominated IDDM1, IDDM2,
IIDM3, etc. Many of these loci are also related to the pre-
disposition to other autoimmune diseases, such as multi-
ple sclerosis, celiac disease, ankylosing spondylitis and
Hashimoto's thyroiditis.
The most important genes are located inside the major
complex of histocompatibilty (MHC) in the region of
class II of the HLA system, particularly molecules DR, DQ
and DP in chromosome 6p21.31 [13]. These are called
IDDM1 and are responsible for about 45% of the genetic
susceptibility of type 1 A diabetes. Most of these data
come from Caucasian populations from Europe and
North-America. In these studies, approximately 95% of
patients have class II antigens HLADR3 or - DR4 and 55 -
60% of them are heterozygotes DR3/DR4. Genotype
DR3/DR4 offers higher risk for type 1 A diabetes, with a
synergic mode of action, followed by homozygote DR4 or
DR3, respectively.
The data suggest that DR4 may offer this susceptibility in
a dominant manner, while DR3 as a recessive feature. The
latest studies using molecular biology techniques have
demonstrated that the locus HLA-DQ is more narrowly
associated with the susceptibility to type 1 A diabetes.
Such locus codifies important proteins at the presentation
and recognition of antigens by the immune system. In
Caucasians, the heterodimers HLA-DQ (alpha chains
denominated DQA1 and beta chains, DQB1) codified by
the alleles DQA1*0301, DQB1*0302 and DQA1*0501,
DQB1*0201 have the strongest association with type 1 A
diabetes and are respectively not balanced at the connec-Diabetology & Metabolic Syndrome 2009, 1:25 http://www.dmsjournal.com/content/1/1/25
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tion to alleles HLADR4 and DR3. On the other hand,
among four common DR2 haplotypes, observed in Cau-
casians, DQA1*0102, DQB1*0602, DRB1*1501 are neg-
atively associated with type 1 A diabetes and are related in
less than 1% of the majority of populations studied,
including Asians, Afro-Americans and Mexican-Ameri-
cans. This protection seems to have a dominant effect, as
the presence of DQB1*0602 protects from diabetes, with
rare exceptions, even in the concomitance of alleles of the
HLA system of high risk of the disease. In other ethnical
groups, the susceptibility for type 1 A diabetes associated
with the genes of the HLA system may involve other alle-
les. Particularly in Brazil, the latest studies in populations
of the Northeast [14] and Southeast [15] show higher fre-
quency of antigens DRB1*03 and DRB1*04 in type 1 dia-
betes than in normal controls. One of the genes related to
the protection is DRB1*11 in both Brazilian populations
studied [14,15].
For nearly 20 years, Bell et al[16] found out that variations
in the number of nucleotide elements repeated (Variable
Number of Tanden Repeats - VNTR) of the 5' portion of the
insulin gene were associated with the development of type
1 A diabetes. A longer group of repetitions was associated
with a reduced risk of diabetes. Such studies have been
replicated and have demonstrated that the important
locus is clearly limited to the insulin gene [17]. It is
denominated IDDM2, located in chromosome 11p15.5
and contributes with approximately 10% of this disease
susceptibility. One of the mechanisms suggested for the
susceptibility and resistance associated with IDDM2 is
related to the influence of VNTR in the transcription of
insulin in the thymus, necessary to establish self-tolerance
during body growth and development.
In a third place of this disease prediction is a lymphocyte
specific phosphatase (PTPN22) gene [18].
Another locus associated with a modulation of the
immune response and with type 1 A diabetes, in some
populations, is IDDM12 in chromosome 2q33, related to
a protein 4 of cytotoxic T lymphocytes (CTLA-4)[19].
In summary, IDDM1 and IDDM2 compete to approxi-
mately 50% of the family aggregation of type1 A diabetes.
The remaining 50% probably occur due to additional
inherited polymorphisms/mutations. The lack of 100%
concordance in identical twins could be due to somatic
mutations, gene rearrangements by chance (e.g., rear-
rangements in T cell receptors) or to environmental fac-
tors.
Ultimately, it is important to emphasize that genes may
have unique behavior among autoimmune diseases,
where a group is related to susceptibility and another is
related to a significant protection and, many times, sur-
passing susceptibility. Studies using recent techniques for
identifying genes and the formation of cooperative study
groups must increase the speed of appearance of suscepti-
bility genes for type 1 A diabetes.
Environmental Factors
The incidence of type 1A diabetes has increased dramati-
cally in many countries during the past four decades; it is
likely that some factors in the environment are changing.
Several environmental factors have already been associ-
ated with the development of type 1 A diabetes, such as
viruses, certain constituents of diet and preservatives food.
The gastrointestinal tract is likely the main system through
which non-self antigens gain access. Recent data from lit-
erature have emphasized the importance of the intestinal
barrier, which is an entry door for viruses and proteins. In
early childhood, such barrier is immature, which allows
the passage of several antigens, and when these antigens
are presented to T lymphocytes by the antigen presenting
cells (macrophages), they will trigger an immune
response which might result in a autoimmune process.
Fasano A et al [20,21] have recently reported a novel pro-
tein, zonulin, that modulates intestinal permeability by
disassembling the intercellular tight junctions. Such pro-
tein may be assessed in the plasma and studies demon-
strate that its serum concentration is increased in patients
with type 1 A diabetes in relation to their relatives and to
controls[22], suggesting that a possible link between
genetic susceptibility, increased intestinal permeability,
environmental exposure to non-self antigens and devel-
opment of autoimmune disease.
The influence of several environmental factors in the
development of type 1 A diabetes, such as birth-related
factors (type of birth, new-born weight), infections, vacci-
nations, diet components and psychosocial factors are
being assessed in a longitudinal study with children since
their first months of life up to the age of 15 (TEDDY
study). People interested in such study may enroll
through the electronic address http://Teddy.epi.usf.edu/
TEDDY/index.htm.
Autoimmune Process
The selective destruction of beta cells of pancreatic islets in
T1ADM is the result of a complex interrelation among
beta cells, the immune system and environmental factors
in individuals genetically susceptible. However, the mech-
anisms which start the changes in this interrelation and
lead to the development of T1DM are not yet fully clari-
fied and, up to now, there are no specific genes or proteins
for most of the cases of T1ADM.
Proteins are involved in most cellular processes and the
cumulative expression of certain proteins may reflect the
specific activities of these cells, thus proteomics may beDiabetology & Metabolic Syndrome 2009, 1:25 http://www.dmsjournal.com/content/1/1/25
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useful to describe the protein profile expression of cells
and of their diabetic phenotype. In this sense, the study of
proteomics and metabolomics is an area which seeks the
development of methods able to characterize, through
biologic samples, bioindicators able to diagnose diseases
in initial stage, to predict levels of susceptibility and to
monitor the disease progression and its response to thera-
pies.
Proteomics has been applied in studies of beta cell differ-
entiation, exposure of islets to cytokines, manipulation of
the nutritional pattern of islets and of transplanted cells.
Though these studies have revealed a complex and
detailed scene of the protein expression profiles of these
cells, their functional implications have not been clarified
yet. Up to now, data indicate that beta cells participate
actively in their self-destruction during the development
of T1DM. Likewise, it seems that there is not any isolated
protein responsible for the disease development, but there
are serial reactions which favor the transition of dynamic
stability of healthy beta cells to dynamic instability and
eventual destruction of beta cells [23].
Considering the above mentioned, we may infer that the
T1DM prevention is difficult. It is supposed that, in the
autoimmune process evolution, individuals produce dif-
ferent proteins, antigens with the expression of different
epitopes which were not detected initially, contributing to
the process perpetuation. According to the suggestion of a
recent article[24] in the beginning of the autoimmune
process against pancreatic beta cells, we may have three or
more antigens, but at the end, there are endless antigens
which are activating the process, i.e., the greater the beta
cell lesion, the more antigens are expressed, which will
reactivate the process. This proposal covers a new concept
for the natural history of T1ADM which, in its preclinical
stage, would be characterized by a succession of relapses
and remissions with interrelation between regulatory T
cells (T-regs) and effectors cells, and regeneration of beta
cells up to the moment when the percentage of beta cell
destruction would no longer allow a proper insulin secre-
tion, resulting in the expression of hyperglycemia. Within
this context, it becomes important to mention the low
capacity of regeneration/neogenesis of beta cells mainly
when they are exposed to hyperglycemia, which is a stim-
ulus metabolic factor to the insulin secretion, but it is also
glycotoxic. When proper glycemic control is instituted at
the beginning of the disease, these cells have acquiescence
and may to keep the levels of C-peptide secretion for a
additional period of time.
After presenting the antigen by the macrophages to T lym-
phocytes, at least four types of answer may be induced in
the immune system: Th1 (cellular immune response), Th2
(humoral immune response), Th17 (cellular immune
response potentialization) and T-regs (which take the
control of immune cellular reactions). Nowadays, T1DM
is considered a T- reg disease, both by its decrease or by its
function alteration (e.g., T lymphocytes of Th1 response
with Th17 which do not obey the regulation of T- reg
cells). This was confirmed by the publication of T1DM
cases in individuals who did not produce antibodies
through congenital agamaglobulinemia [25,26]. In such
individuals, the Th2 response was absent and thus there
was no antibody production. At the same time, it is also
known that during the pathogenetic process, peripancre-
atic T lymphocytes play an important role in the transmis-
sion of local reactions in islets to systemic cells [27].
The anti-islet antibodies circulating also express the
inflammatory lesion taking place in the pancreas. In
T1ADM the most studies autoantibodies are classical anti-
islet (evaluated through the indirect immunofluorescence
method and using as substract cry preserved human pan-
creas sections), glutamic acid decarboxylase antibodies
(GADA), anti-tyrosine-phosphatase (IA2/ICA512) anti-
bodies and anti-insulin autoantibodies. The presence of
autoimmunity against the pancreatic islets is considered
when the individual has one or more antibodies persist-
ent for at least 3 to 6 months. It is important to confirm
these antibodies at least two times in three different occa-
sions.
Antigens ICA512 (IA-2) and later IA-2 β (fogrin-phos-
phatase of insulinoma granules) were isolated independ-
ently by different investigators [28-30]. Almost all
antibodies which react with IA-2β also react with IA-2,
while approximately 10% of patients who develop
T1ADM have antibodies reacting against IA2, but not IA-
2β. Thus, during the routine, the IA-2β essay is unneces-
sary.
So far, insulin and pro-insulin are the only specific anti-
gens of beta cells (all the other antigens described can also
to be founded at other cells). The insulin molecule
epitope recognized by the liquid phase essays seems to be
homogeneous [31]. The anti-insulin antibodies react with
conformational molecule epitope (not against chains A or
B separately) [32]. Nowadays, studies has been shown
that this epitope is between the positions 23 and 30 in the
insulin beta chain. Essays for anti-insulin antibodies have
more specificity for the disease than the ones against
proinsulin. Anti-insulin antibody values correlate
inversely with the age when T1ADM develops. Thus, val-
ues above 2000 nU/ml are almost exclusively present in
children who develop this disease before the age of 5 and
less than 50% of the individuals who develop T1ADM
after the age of 15 years old may have these autoantibod-
ies. Such antibody value is, to some degree, genetically
determined and associated with DR4 [33], DQ8 [32],Diabetology & Metabolic Syndrome 2009, 1:25 http://www.dmsjournal.com/content/1/1/25
Page 5 of 8
(page number not for citation purposes)
DQA1*0102, 0201,0301, 0401 [33]. There are data sug-
gesting that the anti-insulin antibody value among indi-
viduals with positive ICA is inversally related to time of
their evolution to the clinical disease [34]. Usually, anti-
insulin antibodies are the first to appear in children who
develop T1DM [34-36], mainly in children below 1 year
of age. From five children with early (around 8 months
old) high anti-insulin antibodies titers, 4 developed
T1ADM below the age of 3 years old [35].
Among T1ADM relatives children who are persistently
positive only to anti-insulin antibodies rarely develop
clinical T1DM [33], but a high percentage of those who
show another anti-islet cell antibody evolve to T1ADM
after 10 years of age. Adolescents and adults present low
concentration of anti-insulin antibodies.
The use of vaccines constituted from fragments 9-23 of the
insulin B chain, as recently performed with GAD-65, has
been tested in experimental T1ADM models to verify their
immunomodulate power in the natural history of the dis-
ease [37].
The last of antigens described in the autoimmune process
against pancreatic beta cells was one of the bivalent cation
(zinc) transporters [38]. Such antigen was characterized
through the microarray technique and showed specificity
of approximately 80% and high clonal pancreatic fre-
quency. When this new antibody were analyzed together
the antibodies previously described (GADA, anti-insulin
and anti-IA2), it was possible to increase the autoimmune
T1DM diagnosis from 80-85% to 98.2%.
The analysis concerning the evolution profiles of individ-
uals with multiple anti-islet autoantibodies was assessed
in the DAISY study [39]. In this study where children are
assessed consecutively since birth regarding these autoan-
tibodies and glucose tolerance, it was possible to charac-
terize three evolution profiles: 1- Positive transitory
(individuals transitorily positive for antibodies who do
not develop the disease); 2- Non-diabetics (individuals
persistently positive for autoantibodies who do not
develop the disease) and 3- Pre-diabetics (individuals per-
sistently positive for multiple autoantibodies who
develop the disease).
The beta cell recovery function after the clinical diagnosis
of the disease is extremely rare. One report [40], a few
years ago, shown a patient (male, 13 years old) with a
classical T1DM(low C-peptide secretion,
DQB1*0303,0501), that was initially treated with insulin
but it was discontinued after eleven months. Four years
after de clinical diagnosis the reevaluation of this patient
showed an improvement in the C-peptide secretion and
normal glucose tolerance. The immunological assessment
showed that GADA were initially positive, but the concen-
tration was low (± 10 U/ml), persisting weakly positive (±
2 U/ml) and anti-insulin and IA2 autoantibodies which
were initially positive became negative later. At the same
time, the lymphocyte response to proinsulin showed ele-
vated concentration of interleukin 10, which is one of the
protective interleukins for the autoimmune T1DM proc-
ess and trophy for T-reg cells, demonstrating the impor-
tant role of these cells in the process.
However, this patient evolution is an exception, as in
most cases there is a progressive decline in C-peptide
secretion during the natural history of this disease, follow-
ing the start of glycemic instability. In our experience,
approximately 60% of T1DM with less than 6 months of
clinical diagnosis present residual C-peptide secretion
(baseline > 0.6 ng/ml) but which presents a significant
drop after 2 to 3 three years of diagnosis and only 3% of
individuals over 5 years of diagnosis present positive C-
peptide secretion.
Preservation of the residual C-peptide secretion
Today, one of the therapeutic goals in T1DM is the preser-
vation of the residual C-peptide secretion that is detected
in a significant percentage of patients at diagnosis and
which potentially may influence the clinical course of the
disease.
Several studies have been demonstrated that residual C-
peptide secretion, after T1ADM diagnosis, depends on
genetic factors, the patient's age at the diabetes diagnosis,
the number of anti-islet antibodies and the residual C-
peptide secretion. At the same way, intensive insulin ther-
apy and immunomodulators drugs may be useful in this
direction.
Regarding genetic factors, the first ones studied were from
the HLA system. Among these, A24+DQA1+03+ and DR9+
have been associated to a higher velocity of C-peptide lev-
els decrease. Patients who do not have these genes would
keep a better beta cell function and higher C-peptide
secretion [41].
Two other genetic factors related to residual C-peptide
secretion are PTPN-P22 (protein tyrosine phosphatase non-
receptor type 2[42] and one of the vitamin D receptor pol-
ymorphism (Fok1)[43].
PTPN22 gene codifies a lymphoid specific phosphatase
synthesis, known as LYP, which is important to inhibit T
lymphocites activation. A change in the LYP function
leads to an alteration in regulatory T cells CD4+CD25+,
making the system less powerful to suppress immune
response against autoantigens. The residual C-peptide
secretion follow-up on the first 12 months of the diseaseDiabetology & Metabolic Syndrome 2009, 1:25 http://www.dmsjournal.com/content/1/1/25
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in T1DM patients showed that it decreased in patients
who had alterations in such gene [42].
Among unconventional actions of this vitamin is its
immunomodulating function [43]. In this way, we assess
the relation of the frequency of one of vitamin D poly-
morphism receptor, FOK-1, in a group of T1DM with 7
years average period of diagnosis and we verified that the
patients who had this polymorphism presented lower
residual C-peptide secretion [44].
It is classically known that children and adolescents (0 to
17 years old) present at T1DM diagnosis a lower C-pep-
tide response to a mixed meal than adults [45]. However,
there are recent literature data which demonstrates that,
despite this initially higher C-peptide reserve in adults, the
dropping speed after diagnosis is similar in young patients
[46].
Similar data we found in a univariated analysis study
(with fasting C-peptide as depending variable) on a
T1DM group, where we verified a positive correlation with
the age of the patient at clinical diagnosis (r = 0.270; p =
0.001) and negative with the disease duration (r = -0.652;
p < 0.001) and with the HbA1c value (r = -0.176; p =
0.029) of our population. So it was demonstrated that,
apart from patients' age, disease duration as the exposure
to hyperglycemia time are also important to the mainte-
nance of residual C-peptide secretion.
Another widely discussed aspect in literature is the ability
of pancreatic beta cells to regenerate. In a recent case
report, where it was possible to assess this factor in a pan-
creas sample from an 89-year-old patient, T1DM (GADA,
IA2 positive and lower fasting C-peptide) of recent diag-
nosis, submitted to surgery to neo pancreatic duct. Dupli-
cating beta cells were detected in the pancreatic tissue
through immunohistochemical analysis and potassium
channel indicators [47]. Such case study shows that a
potential pancreatic beta cell regeneration is a possibility
to be considered while we are discussing the residual C-
peptide secretion in T1DM.
The number of anti-islet auto-antibodies during the pre-
diabetic stage and at diagnosis of T1DM shown a inverse
relation with the residual beta cell [48]. This is easily ver-
ified when we compare T1DM in children and LADA [49].
At T1DM diagnosis, apart from the autoimmune insult,
beta cells are being submitted to hyperglycemia itself by
the glycotoxic effect, which also cooperates to decrease C-
peptide secretion. This last effect could be demonstrated
when a residual insulin secretion was compared in two
groups of T1DM with the same clinical features during the
first two years from clinical diagnosis, one submitted to
intensive insulin therapy and other under conventional
therapy [50]. In this study, it was observed that even
through both groups present the same residual C-peptide
secretion at diagnosis and after the 1st follow-up year, by
the end of the 2nd year it was significantly higher in the
intensive therapy group. However, it has been discussed if
such effect was obtained through the removal of glycotox-
icity or through the insulin immunomodulate effect.
Regarding immunomodulators, we evaluated nicotina-
mide in a double blind study during the 1st year of T1DM
diagnosis. In this study although the fasting C-peptide did
not change, we did not see any differences between
patients who used this vitamin and placebo [51].
Since a few years ago, some studies have been conducted
using as immunomodulators the antigens involved in the
autoimmune process against beta cells.
One of the first these clinical trials was a double-blind
study, stage II which used a heat-shock protein peptide
(Diapep27) [52]. In this study recently diagnosed T1DM
patients received this peptide at their clinical diagnosis,
and 1 to 6 months later. It was demonstrated that the
group which received this vaccine presented significantly
higher residual C-peptide secretion from the 7th month
and this result was until the end of the study (10th
month), while in the placebo group, there was a progres-
sive reduction in the fasting-C peptide since the 1st month
of diagnosis.
Another study in this way used monoclonal anti-CD3 [53]
antibody, which was also able to cooperate to C-peptide
preservation during the 1st year of diagnosis.
The most recent study for the denominated "secondary
prevention of T1DM" used vaccine with GAD-65[54]. In
this study, recently diagnosed T1DM patients received 20
μg GAD-alum on the 1st and 30th days of the protocol. It
was demonstrated through this study, for patients who
received this vaccine up to 6 months after clinical diagno-
sis, that the fasting C-peptide was significantly higher than
the placebo group on the 10th and 30th month of the
study.
The secondary prevention of T1DM has acquired increas-
ing importance in the last few years due to the insuffi-
ciency of the latest large studies [54,55] for primary
prevention and to the positive effect of the C-peptide
residual secretion to prevent hypoglycemia[56] and the
prevention of diabetic microangiopathy (nephropathy
and neuropathy)[57]. These last actions should be related
to a higher stability of glycemia in these individuals and
to possible actions which would be intermediated
through the insulin receptor or a specific C-peptide recep-Diabetology & Metabolic Syndrome 2009, 1:25 http://www.dmsjournal.com/content/1/1/25
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tor. Such "hormone" would supposedly act through G
protein, C-peptide receptor and protein kinase C (PKC)
and MAPK and nuclear transcription factors [58]. Renal,
circulatory and neural clinical actions have been related to
the C-peptide [59].
Conclusion
In short, T1DM is a progressive autoimmune disease
mediated by T cells with destruction of beta cells. Up to
now, we do not have precise methods to assess the beta
cell mass, "in vivo" or "ex-vivo". The studies about its
genetic susceptibility show strong association with class II
antigens of the HLA system (particularly DQ). Other asso-
ciations are weaker and depend on the studied popula-
tion. A combination of precipitating events (virus, food
factors and others) must occur at the beginning of the dis-
ease, and the intestinal barrier must play an important
role in this process. There is a silent loss (immuno-medi-
ated) of the beta cells mass which velocity has an inverse
relation with the age, but it is influenced by genetic and
metabolic factors. However, in the clinical diagnosis of
the disease, there is a significant reserve of functioning
beta cells. The goal of secondary prevention, by the immu-
nomodulation of the process, is the preservation of such
functional beta-cell reserve. It may be assessed through C-
peptide values, which are important for glycemia stability
and for the prevention of chronic complications in this
disease.
However, the determinant risk factors of T1ADM, the
autoimmune response initiators, the mechanisms which
regulate the process toward beta cell failure and the factors
which determine the time of clinical diabetes arrive are
not fully known yet.
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